Shopping Cart

Remove All

Your shopping cart is currently empty

Proceed to checkout Continue shopping

Fanapanel hydrate

Name: Fanapanel hydrate
Brand: TargetMol
SKU: T13405
Rating: 4.5 (1 reviews)

Copy Product Info

😃Good

Catalog No. T13405Cas No. 1255517-78-2

Alias ZK200775 (hydrate), MPQX hydrate

Fanapanel hydrate is a highly selective antagonist of AMPA/kainate with little activity against NMDA(Ki of 3.2 nM, 100 nM, and 8.5 μM against quisqualate, kainate, and NMDA, respectively).

Fanapanel hydrate

Copy Product Info

😃Good

Catalog No. T13405Alias ZK200775 (hydrate), MPQX hydrateCas No. 1255517-78-2

Fanapanel hydrate is a highly selective antagonist of AMPA/kainate with little activity against NMDA(Ki of 3.2 nM, 100 nM, and 8.5 μM against quisqualate, kainate, and NMDA, respectively).

Pack Size	Price	USA Warehouse	Global Warehouse	Quantity
2 mg	$72	5 days	5 days

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products.However, due to objective factors, there is a small probability that the synthesis may not be successful during the R&D process. We appreciate your understanding.If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Resource Download

Product Introduction

Bioactivity

Description	Fanapanel hydrate is a highly selective antagonist of AMPA/kainate with little activity against NMDA(Ki of 3.2 nM, 100 nM, and 8.5 μM against quisqualate, kainate, and NMDA, respectively).
In vivo	In mice, ZK200775 elevated the threshold for AMPA- and kainate-induced clonic seizures with a THRD50 (threshold dose) of 2.9 (1.7–4.6) and 1.6 (1.3–2.0) mg/kg i.v., respectively, while the threshold for NMDA-induced seizures increased only at a THRD50 of 24.1 (21.9–26.5) mg/kg i.v., which affected motor coordination in the rotating rod with an ED50 of 14.6 (12.1–17.6) mg/kg. ZK200775 at doses of 10 and 30 mg/kg (intravenously) reduced muscle tone in hereditary spastic rats [1]. ZK200775 at 3.0 mg/kg, but not at 1.5 or 6.0 mg/kg, significantly reduced nicotine-induced (0.6 mg/kg) DA release in NACC and nicotine-stimulated LMA. ZK200775 (1.5, 3.0, 6.0 mg/kg) alone influenced neither DA release nor LMA. ZK200775 showed 34-fold selectivity for AMPA receptors compared to NMDA receptors and no affinity to nicotine receptors [2].
Synonyms	ZK200775 (hydrate), MPQX hydrate

Chemical Properties

Molecular Weight	427.27
Formula	C₁₄H₁₇F₃N₃O₇P
Cas No.	1255517-78-2
Smiles	O=C1NC=2C=C(C(=CC2N(C1=O)CP(=O)(O)O)N3CCOCC3)C(F)(F)F.O
Relative Density.	no data available

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 5 mg/mL (11.7 mM), Sonication is recommended.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.3404 mL	11.7022 mL	23.4044 mL	117.0220 mL
5 mM	0.4681 mL	2.3404 mL	4.6809 mL	23.4044 mL
10 mM	0.2340 mL	1.1702 mL	2.3404 mL	11.7022 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc